Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04705129
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT04668365
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04662255
- Locations
- 🇺🇸
Mercy Health-Paducah Medical Oncology and Hematology, Paducah, Kentucky, United States
🇺🇸Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 177
- Registration Number
- NCT04643470
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04551963
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺John Flynn Private Hospital, Tugun, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 13
- Registration Number
- NCT04470908
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04458610
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 66
- Registration Number
- NCT04436107
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT04382586
- Locations
- 🇺🇸
St Jude Medical Center, Fullerton, California, United States
🇺🇸Medstar Heath Research Institute Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸John D Archbold Memorial Hospital, Thomasville, Georgia, United States
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 97
- Registration Number
- NCT04282018
- Locations
- 🇦🇺
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺Saint Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.